Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034186 (pyelonephritis)
 6,144 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Urinary tract infections (UTI) are the most common of all the bacterial infections affecting humans during their life span. In adult patients, UTI may be categorized into the following groups: acute uncomplicated cystitis, acute uncomplicated pyelonephritis, recurrent bacterial UTI infections, asymptomatic bacteriuria, complicated UTI, acute and chronic bacterial prostatitis. In patients with uncomplicated cystitis, short-course (3 days) empirical therapy is more effective than single dose therapy. Recurrent cystitis can be effectively managed by continuous antimicrobial prophylaxis. Acute pyelonephritis in patients with anatomically normal urinary tracts should be treated with antimicrobial therapy for 10 to 14 days. Complicated infections require a full 10- to 14-day course of antimicrobial therapy. Urologic evaluation in patients with acute pyelonephritis or recurrent infections should not be routinely performed. Screening for asymptomatic bacteriuria is unnecessary in adults, except in particular circumstances. There is little evidence that UTI in adult patients lead to progressive chronic renal injury, unless complicating factors are concurrently present.
 ...
PMID:[Urinary infections in adults: clinical approach and therapeutic indications]. 772 3

Pefloxacin (Abaktal) was used in treatment of 83 patients: 14 patients with acute pyelonephritis, 5 patients with carbuncle of the kidney, 17 patients with postoperative acute pyelonephritis, 3 patients with urosepsis, 7 patients with acute prostatitis, 18 patients with chronic pyelonephritis in the phase of active inflammation, 9 patients with exacerbation of chronic prostatitis, 3 patients with acute cystitis, 2 patients with acute urethritis and 5 patients with epididymo-orchitis. Two dosage forms of pefloxacin were used i.e. tablets of 400 mg and ampoules of 5 ml containing 400 mg of the active substance. The treatment course amounted to 7-14 days. In the patients with inflammatory infectious diseases of the lower urinary tracts (cystitis and urethritis) the treatment course amounted up to 5 days. The results of the treatment with the ampoule solutions were good and satisfactory. With the use of the tablets the results were unsatisfactory in 3 patients (8.1 per cent). Satisfactory bacteriological efficacy of the treatment was stated in 89.5 per cent of the cases. The adverse reactions such as nausea, vomiting, diarrhea and skin eruption were recorded in 5 patients (6 per cent).
 ...
PMID:[Clinical effectiveness of pefloxacin (abaktal)in the treatment of inflammatory diseases of the kidneys, urinary tracts and genital organs]. 807 66

The choice of operative techniques applicable in urethral strictures and obliterations is rather great today. The author holds that procedures that may entail bladder hypotonia, pyelonephritis, nephrolithiasis, prostatitis, impotence, especially in young patients, should be rejected as ineffective. These complications often result from ignorance of perineal anatomy, erroneous choice of surgical policy leading to bouginage. To avoid it, the surgeon is advised to employ two-stage urethral reconstruction according to B. Johanson. The procedure, proposed in 1950, implies usage of plastic material obtained from penile and scrotal skin. The original variant of the procedure has the disadvantage of confinement only to urethral strictures. We use two new variants of Johanson operation which can abate not only strictures, but obliterations as well. The experience of 1-26-year follow-up indicates feasibility of our modified operations in multiple strictures in combination with other surgical interventions, in urethrorectal and perineal fistulas and in pediatric surgery.
 ...
PMID:[A modification of Johanson's operation in the treatment of urethral strictures and obliterations]. 807 5

As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study. Twenty-six patients, 16 women and 10 men, aged 20 to 56 years, who developed urinary tract infection (UTI) from 6 months to 10 years after renal transplantation were included in the study. Of these patients, 20 (77%) showed cystitis and/or prostatitis and 6 (23%) clinical symptomatology of acute or recurrent pyelonephritis. Patients with obstructive uropathy were excluded. Urine culture was positive for E. coli in 16/26 patients (61.5%) and for proteus mirabilis, klebsiella, staphylococcus aureus in 10/26 (38.5%). All patients were given ciprofloxacin 250 mg x 2 daily for 10 days and the results of the treatment were compared to those of 60 nontransplant patients (controls) with UTI. Fourteen patients (54%) were completely cured and 10(38%) showed improvement, while the respective results in the controls were 68% (41/60) and 28%. Relapses occurred in two patients, one in each group. Serious side effects were not observed. It is concluded that ciprofloxacin is an effective and safe drug for the treatment of UTI in renal transplant patients.
 ...
PMID:Treatment of urinary tract infections with ciprofloxacin after renal transplantation. 833 29

A clinical trial of cephmethasone (Sankyo, Japan) has been performed in 40 patients with pyelonephritis. 3 patients with chronic cystitis. 19 patients with chronic prostatitis. Cephmethasone, cephalosporin of the second generation, is active against gram-positive and gram-negative agents, hospital infection. The treatment course consists of 4-14 daily doses of 2-4 g. Bacterial elimination was reached in 79.5% of the cases with a complete response in 70% and partial one in 30% of patients. Side effects were not registered. As a highly active wide-spectrum antibiotic, cephmethasone is offered for treatment of urinary infections. Cephmethasone monotherapy provides a rapid relief of cystitis, prostatitis and pyelonephritis symptoms.
 ...
PMID:[The use of cephmetazon in treating infectious inflammatory diseases of the upper and lower urinary tract]. 857 75

To date transurethral laser ablation of the prostate (TULAP) in benign prostatic hyperplasia (BPH) is the commonest form of transurethral laser surgery. The invention of the so-called "sidefire" laser fibre was the prerequisite condition for effective transurethral laser ablation of the prostate. Since the first transurethral laser ablation in human BPH was performed by Costello in September 1990, a multitude of urologists have adopted this technique. In the meantime, a great many studies have been carried out and a lot of data have been published. The initial, to some extent euphoric, enthusiasm of some urologists as well as some patients, especially in the USA and Europe, has turned into a more critical reflection. There is no doubt at all that TULAP is a feasible alternative treatment method with reasonable results. Especially in the high-risk patient, there is neither severe blood loss nor an uptake of irrigation fluid. It is also beneficial to allow unlimited treatment in patients on anticoagulant medication. Nevertheless, the value of TULAP in comparison to transurethral electroresection of the prostate (TURP), generally accepted as the "gold-standard" in the surgical therapy of BPH, remains unclear. A final assessment will only be possible when further data on mortality, short and long term morbidity and outcome with this method have been presented. Strong evidence exists that the operation can be performed without blood loss and uptake of irrigation fluid. A further advantage seems to be preservation of sexual function, especially anterograde ejaculation in the majority of patients, in comparison to the "gold-standard" TURP. In most studies, the value of TULAP is further compared with regard to the elimination of obstruction by means of pressure-flow-studies. The aspect most frequently neglected by all investigators to date is the frequency and severity of urinary tract infections (UTI) in patients in whom TULAP is performed. Basically, UTI in the form of cystitis, ascending infections such as male adnexitis or pyelonephritis, prostatitis of the remaining parts of the prostate and catheter-induced urethritis are associated with transurethral surgery in general. Certain data indicate an age-related frequency of UTI. From a rate of approximately 1% of UTI in infants, the frequency rises to 30% in the 8th decade of life. According to these data, one can expect that in a study of TULAP in high risk patients, most of whom are elderly, a large number present for surgery with a preexisting UTI. Other data demonstrate that after 4.5 days 50% and more of patients with an indwelling catheter develop an ascending UTI, although a closed urinary drainage system has been used. In most cases enterobacteriaceae, in 80% Escherichia coli, are detected. Especially in TULAP, a period of prolonged catheterisation has to be expected in the majority of patients. The risk of UTI in the perioperative phase is therefore expected to be higher. There are several higher risks and possibilities of complications in transurethral surgery in patients with UTI. Taking this into account, all our patients routinely undergo low dose antibiotic prophylactic treatment. The frequency of infections of the remaining parts of the prostate after prostatic surgery is strongly correlated to the flow characteristics in the prostatic urethra and to the amount of destruction of the prostatic tissue. Here are further reasons for a higher risk of infection after TULAP. Due to the fact that the prostatic tissue is not removed by a clear cut, but coagulated by laser beam, a rough surface due to tissue necrosis results. This is an ideal culture medium for bacteria aggravated by the disturbed laminar flow in the prostatic urethra, which favours an intraprostatic reflux of infected urine. There is evidence that UTI are the most important factor of morbidity during the first weeks after TULAP because of their bothersome symptoms.(ABSTRACT TRUNCATED)
 ...
PMID:Transurethral laser therapy and urinary tract infections. 876 50

The antibiotic policy in 34 Dutch formularies for the treatment of urinary tract infections (UTI) was evaluated. A great variation in antibiotic therapy for the treatment of cystitis was observed: the length of therapy ranged from 1 to 14 days, the agents recommended included older compounds such as trimethoprim-sulfamethoxazole and newer agents such as ciprofloxacin. Recommendations for the treatment of acute pyelonephritis were: a 2 week course of co-trimoxazole in 20 out of 34 formularies. Likewise for acute prostatitis less variation was observed for the length of treatment, i.e. 2 weeks co-trimoxazole, doxycycline or quinolones.
 ...
PMID:Treatment of urinary tract infections in Dutch hospitals. 881 61

Prompt, thorough evaluation is needed when patients present with symptoms of renal colic, acute urinary retention, prostatitis, pyelonephritis, and other urologic emergencies. Primary care physicians have an important role in initial workup and treatment. Once the diagnosis is determined, urologic consultation may be necessary for definitive treatment.
 ...
PMID:Urologic emergencies. Conditions affecting the kidney, ureter, bladder, prostate, and urethra. 885 90

Two hundred and two isolates of gram-positive and gram-negative pathogens of urinary tract infection were tested for their susceptibility to cefpirome. In 64 to 97 per cent of the cases the susceptibility was high and exceeded that of other cephalosporins used in the treatment of urological patients. Cefpirome was used in the treatment of 26 patients with signs of urinary tract infection: 19 patients with pyelonephritis and 7 patients with prostatitis. The antibiotic was administered intravenously in a dose of 1 g twice a day for the treatment course of 5-7-10 days. The clinical and bacteriological efficacies amounted to 92 and 87 per cent respectively. The drug tolerance was good. The results demonstrated that cefpirome was useful in the empirical therapy of urinary tract infection.
 ...
PMID:[Effectiveness of cefpirome in the treatment of complicated infections of the upper and lower urinary tracts]. 912 83

To define the urovirulence properties of Escherichia coli strains producing prostatitis, E. coli strains isolated from men with acute (7 strains) or chronic (23) prostatitis were compared with E. coli isolates from women with pyelonephritis (30), acute cystitis (60), or complicated urinary tract infection (UTI; 30). Strains from prostatitis patients were significantly more likely to express hemolysin than were strains causing complicated UTI (73% vs. 43%; P = .02) and more often demonstrated hybridization with the cytotoxic necrotizing factor-1 (CNF-1) probe (63%) than did strains from women (44%-48%). P fimbrial expression was highest among pyelonephritis (73%) and prostatitis strains (53%) and lowest among E. coli from women with complicated UTI (23%) and cystitis (30%; P < .05, prostatitis strains vs. either of the latter 2 groups). Results suggest that E. coli strains producing prostatitis generally possess urovirulence profiles similar to those of strains from women with acute uncomplicated pyelonephritis and that hemolysin and CNF-1 are especially prevalent in prostatitis strains.
 ...
PMID:Urovirulence determinants in Escherichia coli strains causing prostatitis. 923 13


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>